DEALS THIS WEEK: EISAI PHARMACEUTICAL, ABBVIE, OTSUKA

The main activity of our company is providing pharmaceutical enterprises with high-quality substances and consumables..

DEALS THIS WEEK: EISAI PHARMACEUTICAL, ABBVIE, OTSUKA
Ask question
Our specialists answer any question about your inquiry
19 October 2018
      Eisai Pharmaceutical has signed an agreement with Eurofarma Laboratorios for the marketing and distribution of its anti-obesity drug lorcaserin hydrochloride (BELVIQ in the US) in 17 countries in Latin America and the Caribbean, excluding Brazil.

      Lorcaserin was approved in June 2012 in the US and is a novel chemical entity, which helps patients decrease food intake by stimulating the serotonin 2C receptors in the brain.

      Under the agreement, Eisai will receive a one-off contractual payment and be eligible for milestone-based payments in each country.

      Based in Japan, Eisai is a leading global research and development-based pharmaceutical company, while Eurofarma is a pharmaceutical company based in Brazil.

      The transaction will enable Eisai to market lorcaserin worldwide.

      Abbvie and Novartis’ subsidiary Sandoz have resolved intellectual property litigation with regard to Hyrimoz (adalimumab), the latter’s biosimilar of Humira.

      The two companies have signed a non-exclusive licencing agreement for Hyrimoz. Under this, Abbvie will provide a non-exclusive licence to Sandoz for the intellectual property related to the drug.

      Abbvie also entered similar licensing agreements with other companies for Humira on a country by country basis.

      Adalimumab is a human monoclonal antibody indicated for the treatment of inflammatory disorders such as rheumatoid arthritis and psoriatic arthritis. Sandoz’s biosimilar to adalimumab, Hyrimoz, was approved by the European Commission in July.

      Based in the US, AbbVie is a biopharmaceutical company engaged in research and development, while Sandoz is a Germany-based manufacturer of generic pharmaceuticals and biosimilars.

      Otsuka Pharmaceutical has extended its agreement with Proteus Digital Health to develop and market digital medicines.

      The new agreement includes the development of Abilify Mycite drug-device combination product, which was approved by the US Food and Drug Administration (FDA) for treatment of a number of mental disorders.

      Otsuka has paid $88m to Proteus in the form of equity and other payments under the deal.

      Based in Japan, Otsuka is a pharmaceutical company, while Proteus is a digital medicines company based in the US.

      The collaboration will enable Otsuka to advance its portfolio of digital medicines to assist patients with severe mental illnesses.

      MEI Pharma has signed a clinical collaboration agreement with BeiGene. The deal evaluate the safety and efficacy of MEI’s investigational phosphatidylinositol 3-kinase inhibitor, ME-401, in combination with the BeiGene’s zanubrutinib in patients with B-cell malignancies.

      MEI will alter its ongoing Phase Ib trial to evaluate ME-401 in combination with zanubrutinib under the agreement. The study’s cost will be shared equally by the companies.

      Based in the US, MEI Pharma is a pharmaceutical company focused on identifying new therapies in the field of oncology. BeiGene is a Chinese commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics.